Company Overview
Snapshot
Founded in July 2024 by Ido Goldberg and Refael Minnes, Emsight operates with 1–10 employees. The company has raised $400K across one funding round. In September 2024, Emsight secured a grant from the Israel Innovation Authority.
Business overview
Emsight is pioneering groundbreaking, non-invasive cataract treatment solutions within the Health Tech & Life Sciences sector. The company develops an innovative medical device based on non-ionizing electromagnetic radiation, designed to address the root cause of cataracts without surgical intervention. This technology aims to provide a safer, more cost-effective alternative to traditional procedures, empowering eye clinics to deliver advanced care to patients across various stages of cataract development with minimal recovery time. Emsight primarily serves the healthcare market, specifically targeting providers and ophthalmologists.
Log in to access full profile ›Company Intelligence Q&A
- When was Emsight founded and by whom?
- Emsight was founded in July 2024 by co-founders Ido Goldberg and Refael Minnes.
- What is Emsight's core technology?
- Emsight is developing a non-invasive cataract treatment solution using an innovative medical device based on non-ionizing electromagnetic radiation, designed to target cataract formation at its core.
- What problem does Emsight aim to solve in eye care?
- Emsight aims to revolutionize cataract treatment by offering a non-surgical alternative to traditional procedures, providing a safer and more cost-effective solution for ophthalmologists and patients.
- What is Emsight's primary market focus?
- Emsight focuses on the healthcare market, specifically serving providers and eye clinics to deliver advanced cataract care to patients.
- What is Emsight's current product development stage?
- Emsight's product is currently in the R&D stage, focusing on developing its non-invasive cataract treatment technology.